About the JPG
The JPG is the voice of the Japanese life sciences industry in the UK, made up of eleven companies whose global HQs are based in Japan. Our approach is positive engagement with Government on promoting UK Life Sciences. Our ambition is to partner with Government to optimise Japanese engagement with our ecosystem.
Our members are Astellas, Chugai, Daiichi-Sankyo, Eisai, Kyowa Kirin, Mitsubishi Tanabe, Ono, Otsuka, Santen, Shionogi and Takeda.
These companies represent a broad range of organisations, of varying size and footprint in the UK. Our members are a diverse group, from global top 10 pharma, through to specialised companies whose growth is accelerating in the UK. Turnover in the UK last year for the group as a whole, was in excess of £575 million.
Vast majority of JPG members currently have their European headquarters in the UK, making their presence here important not just to the UK, but to the European region.
As a group the JPG employs approximately 2700 people in the UK. Our members invest in basic research and all phases of clinical development, as well as partnering with biotech and research institutions.
JPG members are looking to bring innovation to the UK, with an impressive around 30 launches expected including 22 new chemical entities (NCEs) expected in the next 5 years by the companies in the Group.
Therapeutic categories of products covered by JPG members include; anti-infectives (including new antibiotics), cardiovascular, diabetes, dermatology, endocrinology, gastroenterology, haematology, immunology, metabolism, mental health (schizophrenia), nephrology, neurology (e.g. ADHD, Alzheimer’s, epilepsy, multiple sclerosis), oncology, ophthalmology, pain, transplant, urology and vaccines.
Members are also increasingly looking at innovations in digital health, AI, gene therapy and the roles they can have in enhancing patient care and outcomes.
We are very proud of the collective efforts of our global companies in the fight against COVID. As of November 2021, JPG member company innovation spanned four vaccine candidates, three of which involved novel technology, and four antivirals across the spectrum of patients with asymptomatic, mild to moderate and severe, COVID-19. Our members continue to support five international research collaborations aiming to speed up the development of COVID-19 vaccines and treatments.